Industry Organizations Assist Pharma During the Pandemic and Beyond
Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology, Regulatory Sourcebook, September 2021
Volume 2021 eBook
Issue 3
Pages: 42-45
Pharmaceutical Technology checked in with AAPS and IPEC-Americas to get an update on how the organizations are navigating the pandemic and planning for the future.
LEOWOLFERT - STOCK.ADOBE.COM
Pharmaceutical development, manufacturing, and quality efforts are often advanced by the work of industry associations and members through conferences, training sessions, publications, and working groups. These efforts continued during the past 18 months, despite restrictions posed by the COVID-19 pandemic. The American Association of Pharmaceutical Scientists (AAPS) and the International Pharmaceutical Excipients Council of the Americas (IPEC-Americas) shared recent activities and industry contributions with Pharmaceutical Technology.Read in this article in Pharmaceutical Technology’s September 2021 Regulatory Sourcebook eBook.
Read in this article in Pharmaceutical Technology’s September 2021 Regulatory Sourcebook eBook.
Article Details
Pharmaceutical Technology
eBook: Regulatory Sourcebook
September 2021
Pages: 42-45
Citation
When referring to this article, please cite it as PharmTech Editors, “Industry Organizations Assist Pharma During the Pandemic and Beyond,” Pharmaceutical Technology’s Regulatory Sourcebook eBook (September 2021).
Articles in this issue
Understanding Combination Product Regulations
Considering Titanium Dioxide Regulatory Changes
The Real Danger of Substandard and Counterfeit COVID-19 Vaccines
Changing the Course of Drug Shortages
Sampling and Testing Nomenclature for Pharmaceutical Analysis: A Simplified Approach
Sampling and Testing Nomenclature for Pharmaceutical Analysis: A Review of Current Practices
Industry Organizations Assist Pharma During the Pandemic and Beyond
Mapping Out Pharma’s Regulatory Future in Europe
Recent Videos
Related Content
FDA Grants Full Approval for Symptomatic Tenosynovial Giant Cell Tumor Treatment
February 18th 2025Article
Tenosynovial giant cell tumor (TGCT) is rare and non-malignant, forming in or near joints, but which if left untreated can cause damage to joints and surrounding tissue, potentially leading to significant disability.
